You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 維亞生物(1873.HK)高開4.01% 擬25.6億元收購朗華製藥80%股權
格隆匯 08-10 09:25
格隆匯8月10日丨維亞生物(1873.HK)高開4.01%,報10.9港元,逼近上週五(7日)盤中創下的歷史最高位11港元,暫成交324萬港元,最新總市值204億港元。維亞生物昨晚發公告稱,2020年8月8日,公司間接全資附屬公司維亞生物科技(上海)作為買方訂立股份購買協議,據此,維亞生物科技(上海)同意收購及賣方同意共同出售朗華製藥80%的股權,代價為人民幣25.60億元(相當於約28.42億港元),將以現金支付。朗華製藥集團為一間位於浙江省台州的綜合及全面藥品研發及製造公司,主要從事小分子原料藥和中間體生產和CDMO業務。完成後,朗華製藥將成為公司的非全資附屬公司,並將作為經擴大集團小分子藥及中間體的唯一CDMO平台。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account